Topical Clascoterone Cream for Treating Acneiform Rosacea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of Clascoterone cream 1% in patients diagnosed with papulopustular rosacea. The study aims to demonstrate the cream's ability to reduce the size of sebaceous glands, which are associated with the condition. Participants will be required to comply with study instructions and attend all visits while maintaining their usual skincare routines. The trial is interventional and is currently in Phase 2.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women ages 18+.
* Diagnosis of rosacea type 2 (papulopustular).
* Available and willing to comply with study instructions and attend all study visits.
* Able and willing to provide written and verbal informed consent.
* Subject has used the same type and brand of make-up, other facial products, and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the baseline visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion Criteria:

* Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
* Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
* Pregnant, lactating, or is planning to become pregnant during the study.
* Subject is currently enrolled in an investigational drug or device study.
* Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (baseline).
* Study participant has facial hair that could interfere with the study assessments in the opinion of the investigator.
* Study participant is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
* Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.
* Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.

Where it's running

• New York Harbor VA Brooklyn Campus
  Brooklyn, New York, United States Recruiting

Study contacts

• Principal investigator: Jared Jagdeo, MD MS — SUNY Downstate Health Sciences University Department of Dermatology
• Study coordinator: Kayla N Zafar, BA
• Email: kayla.zafar@va.gov
• Phone: 718-836-6600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remibrutinib for moderate-to-severe papulopustular rosacea

  A Phase 2 study tests whether remibrutinib can reduce inflammatory facial lesions in adults with moderate-to-severe papulopustular rosacea.

  Recruiting at 17 sites Phase 2 Novartis · El Paso, Texas and 16 other locations · NCT07681271

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.